Biogen Inc.
GB ˙ LSE ˙ US09062X1037
197,61 $ ↓ -0,67 (-0,34%)
2026-06-05
DEL PRIS
SecurityGB:0R1B / Biogen Inc.
InstitutionCrossmark Global Holdings, Inc.
Latest Disclosed Ownership9,961 shares
Latest Disclosed Value $ 1,826,150
Crossmark Global Holdings, Inc. reports 1.32% decrease in ownership of 0R1B / Biogen Inc.

On May 11, 2026 - Crossmark Global Holdings, Inc. filed a 13F-HR form disclosing ownership of 9,961 shares of Biogen Inc. (GB:0R1B) valued at $1,784,513 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 3, 2026 disclosing 10,094 shares of Biogen Inc.. This represents a change in shares of -1.32% during the quarter. The current value of the position is $1,968,393 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F BIOGEN COM 09062X103 9,961 -133 -1.32 1,826 2.82 0.0270
2026-02-03 2025-12-31 13F BIOGEN COM 09062X103 10,094 6,436 175.94 1,776 246.88 0.0253
2025-11-12 2025-09-30 13F BIOGEN COM 09062X103 3,658 -282 -7.16 512 3.64 0.0077
2025-08-08 2025-06-30 13F BIOGEN COM 09062X103 3,940 338 9.38 495 0.41 0.0080
2025-04-30 2025-03-31 13F BIOGEN COM 09062X103 3,602 -585 -13.97 493 0.0087
2025-01-16 2024-12-31 13F BIOGEN IDEC COM 09062X103 4,187 -2,870 -40.67 1 -100.00 0.0117
2024-11-04 2024-09-30 13F BIOGEN IDEC COM 09062X103 7,057 -394 -5.29 1 0.00 0.0244
2024-07-29 2024-06-30 13F BIOGEN IDEC COM 09062X103 7,451 -1,807 -19.52 2 0.00 0.0330
2024-05-13 2024-03-31 13F BIOGEN IDEC COM 09062X103 9,258 -269 -2.82 2 -50.00 0.0383
2024-02-13 2023-12-31 13F BIOGEN IDEC COM 09062X103 9,527 -2,255 -19.14 2 -33.33 0.0511
2023-11-08 2023-09-30 13F BIOGEN IDEC COM 09062X103 11,782 -11,265 -48.88 3 -50.00 0.0705
2023-07-31 2023-06-30 13F BIOGEN IDEC COM 09062X103 23,047 -835 -3.50 6 0.00 0.1315
2023-05-12 2023-03-31 13F BIOGEN IDEC COM 09062X103 23,882 712 3.07 7 0.00 0.1563
2023-01-19 2022-12-31 13F BIOGEN IDEC COM 09062X103 23,170 4,602 24.78 6 -99.88 0.1599
2022-11-01 2022-09-30 13F BIOGEN IDEC COM 09062X103 18,568 699 3.91 4,958 36.06 0.1376
2022-07-29 2022-06-30 13F BIOGEN IDEC COM 09062X103 17,869 -319 -1.75 3,644 -4.86 0.0944
2022-05-11 2022-03-31 13F BIOGEN IDEC COM 09062X103 18,188 5,687 45.49 3,830 27.71 0.0854
2022-01-10 2021-12-31 13F BIOGEN IDEC COM 09062X103 12,501 2,555 25.69 2,999 6.54 0.0651
2021-10-21 2021-09-30 13F/A-1 BIOGEN IDEC COM 09062X103 9,946 1,232 14.14 2,815 -6.70 0.0660
2021-10-13 2021-09-30 13F BIOGEN IDEC COM 09062X103 7,817 -897 1,166 0.1334
2021-07-21 2021-06-30 13F BIOGEN IDEC COM 09062X103 8,714 -1,371 -13.59 3,017 6.95 0.0709
2021-04-15 2021-03-31 13F BIOGEN IDEC COM 09062X103 10,085 -632 -5.90 2,821 7.51 0.0699
2021-01-14 2020-12-31 13F BIOGEN IDEC COM 09062X103 10,717 195 1.85 2,624 -12.09 0.0663
2020-10-08 2020-09-30 13F BIOGEN IDEC COM 09062X103 10,522 -177 -1.65 2,985 4.26 0.0837
2020-08-14 2020-06-30 13F BIOGEN IDEC COM 09062X103 10,699 -675 -5.93 2,863 -20.45 0.0835
2020-04-28 2020-03-31 13F BIOGEN IDEC COM 09062X103 11,374 -462 -3.90 3,599 2.48 0.1288
2020-02-06 2019-12-31 13F BIOGEN IDEC COM 09062X103 11,836 -2,307 -16.31 3,512 6.65 0.0965
2019-10-09 2019-09-30 13F BIOGEN IDEC COM 09062X103 14,143 -963 -6.37 3,293 -6.79 0.0961
2019-07-09 2019-06-30 13F BIOGEN IDEC COM 09062X103 15,106 946 6.68 3,533 5.56 0.0991
2019-05-02 2019-03-31 13F BIOGEN IDEC COM 09062X103 14,160 -286 -1.98 3,347 -23.00 0.0950
2019-01-31 2018-12-31 13F BIOGEN IDEC COM 09062X103 14,446 743 5.42 4,347 -10.20 0.1347
2018-11-08 2018-09-30 13F/A-1 BIOGEN IDEC COM 09062X103 13,703 -1,037 -7.04 4,841 13.16 0.1229
2018-11-06 2018-09-30 13F BIOGEN IDEC COM 09062X103 14,740 0 4,278
2018-07-31 2018-06-30 13F BIOGEN IDEC COM 09062X103 14,740 -1,706 -10.37 4,278 -5.00 0.1148
2018-04-16 2018-03-31 13F BIOGEN IDEC COM 09062X103 16,446 1,059 6.88 4,503 -8.14 0.1164
2018-02-05 2017-12-31 13F BIOGEN IDEC COM 09062X103 15,387 -1,133 -6.86 4,902 -5.24 0.1178
2017-10-27 2017-09-30 13F BIOGEN IDEC COM 09062X103 16,520 0 0.00 5,173 0.00 0.1333
2017-10-25 2016-09-30 13F BIOGEN IDEC COM 09062X103 16,520 16,520 5,173 0.1333
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.